



**THE FOUNDATION
FOR SECURE
MARKETS®**

#54348

Date: March 21, 2024

Subject: Graphite Bio, Inc. - Contract Adjustment
Option Symbol: GRPH
New Option Symbol: LENZ1
Date: 03/22/2024

Graphite Bio, Inc. (GRPH) has announced a 1-for-7 reverse stock split and a name, symbol, and CUSIP change in connection with the merger with Lenz Therapeutics, Inc. The merger became effective on March 21, 2024. As a result, each GRPH Common Share will be converted into the right to receive approximately 0.142857 (New) Lenz Therapeutics, Inc. (LENZ) Common Shares. Cash will be paid in lieu of fractional LENZ shares.

Additionally, Graphite Bio, Inc. (GRPH) has announced a Special Cash Dividend of approximately \$1.03 per GRPH Common Share for pre-reverse split GRPH shareholders. The record date is March 18, 2024; payable date is March 21, 2024. The ex-distribution date is March 22, 2024.

Options Contract Adjustment

Effective Date: March 22, 2024

New Multiplier: 100 (e.g., for premium extensions a premium of 1.50 equals \$150; a strike of 5 yields \$500.00).

Contract Multiplier: 1

Strike Prices: No Change

Option Symbol: GRPH changes to LENZ1

Deliverable Per Contract:

- 1) 14 (New) LENZ Therapeutics, Inc. (LENZ) Common Shares
- 2) Approximately \$103.00 Cash (approximately \$1.03 x 100)
- 3) Cash in lieu of approximately 0.2857 LENZ shares

CUSIP: LENZ (New): 52635N103

Pricing

Until the exact cash amount is determined, the underlying price for LENZ1 will be determined as follows:

$$\text{LENZ1} = 0.142857 (\text{LENZ}) + 1.03$$

Delayed Settlement

The LENZ component of the LENZ1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the LENZ1 deliverable until exact cash amount is determined. Upon determination of the exact cash amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.